Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

NCT01145508 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

10

Enrollment

NIH

Sponsor class

Stopped Poor accrual

Conditions

Hormone-Resistant Prostate Cancer
Prostate Adenocarcinoma
Recurrent Prostate Carcinoma
Stage IV Prostate Cancer

Interventions

DRUG: Docetaxel
OTHER: Laboratory Biomarker Analysis
DRUG: Prednisone
BIOLOGICAL: Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine
BIOLOGICAL: Rilimogene Galvacirepvec

Sponsor

National Cancer Institute (NCI)